We are live on ! Find out more

TELA Bio

TELA

Market cap $41.5M

0.9200 USD

-0.0560

5.74%

At close Updated Oct 29, 4:00 PM EDT

1 day

-5.74%

5 days

-8%

1 month

-25.81%

3 months

35.79%

6 months

6.98%

Year to date

-19.3%

1 year

-30.3%

5 years

-92.85%

10 years

-93.11%

About: TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Employees: 218

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 88.9%

Negative 11.1%

TELA Bio to Announce Third Quarter 2026 Financial Results

MALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

TELA Bio to Announce Third Quarter 2026 Financial Results

TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript

TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript

TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product.

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

U.S. stocks settled higher on Friday, with the Dow Jones index recording sharp gains during the session as crude oil retreated on hopes for an Iran-brokered reopening of the Strait of Hormuz.

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

Zacks Investment Research

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company's newly-hired Chief Executive Officer, Heather Getz, with a grant date of August 3, 2026 (the "Getz Grant Date"). The stock options consist of (i) stock options to purchase 1,365,000 shares of common stock (the “Standard Options”) and (ii) premium-priced stock options to purchase 1,005,000 shares of common stock (the “Premium-Options”). Additionally, the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 95,500 shares of its common stock to 11 newly-hired employees, with a grant date of August 4, 2026. The stock options and the restricted stock units discussed above were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Ms. Getz's and each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today.

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference.

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

See News Rankings

Price charts implemented using Lightweight Charts™